Dapagliflozin Generic Approved by FDA on April 6, 2026

The U.S. Food and Drug Administration (FDA) granted initial approval for a generic version of Dapagliflozin on April 6, 2026. This approval, designated as ANDA 211468, was issued to AUROBINDO PHARMA. This milestone introduces a new generic option for a widely used medication.

Background

Dapagliflozin is the active pharmaceutical ingredient in Farxiga, a well-established medication. It belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs are primarily used in the management of various conditions, including type 2 diabetes mellitus, heart failure with reduced ejection fraction, and chronic kidney disease. The original brand-name drug has been a significant therapeutic option for patients in these areas. An Abbreviated New Drug Application (ANDA) approval signifies that the generic drug is bioequivalent to its brand-name counterpart, meaning it works in the same way and provides the same clinical benefit.

What this means

The initial FDA approval of a generic version of Dapagliflozin by AUROBINDO PHARMA is a significant development for patients and the healthcare system. Generic drugs typically offer a more affordable alternative to brand-name medications, which can lead to increased patient access and adherence to treatment. This approval is expected to introduce greater competition in the market for Dapagliflozin, potentially lowering costs for patients and healthcare payers. For clinicians, the availability of a high-quality, bioequivalent generic means they can continue to prescribe an effective treatment option with the added benefit of improved affordability for their patients. The FDA's rigorous review process for ANDAs ensures that generic medications meet the same strict standards for quality, strength, purity, and stability as their brand-name equivalents.

Source

The information regarding this initial generic approval was obtained from the U.S. Food and Drug Administration (FDA) on April 6, 2026. The approval details for ANDA 211468 are publicly accessible via the accessdata.fda.gov database.